Overview

Financials

News Ideas Discussions Technicals Forecast Seasonals Options

ADVM fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

‪46.38 M‬USD

—

−6.39USD

2006

155

Laurent Fischer

adverum.com

About

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

Ownership

‪‪20.89 M‬‬

Free Float shares

‪‪13.83 M‬‬ (66.22%)

Closely held shares

‪‪7.06 M‬‬ (33.78%)

Free Float shares

‪‪13.83 M‬‬ (66.22%)

Closely held shares

‪‪7.06 M‬‬ (33.78%)

Capital structure

Market cap

‪‪46.38 M‬‬

Debt

‪‪93.18 M‬‬

Cash & equivalents

‪‪83.08 M‬‬

Enterprise value

‪‪56.47 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary

‪‪46.38 M‬‬

Price to earning ratio (P/E)

—

Price to sales ratio (P/S)

47.32x

Market Cap

Net income

Revenue

Price to earning ratio (P/E)

—

Price to sales ratio (P/S)

47.32x

Valuation ratios

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Q1 '25

‪0.00‬

‪40.00‬

‪80.00‬

‪120.00‬

‪160.00‬

P/S

Growth and Profitability

Company’s recent performance and margins

Performance

‪−2,740.00%‬

‪−2,680.00%‬

‪−2,620.00%‬

‪−2,560.00%‬

‪−2,500.00%‬

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Q1 '25

‪‪−48.00 M‬‬

‪‪−32.00 M‬‬

‪‪−16.00 M‬‬

‪0.00‬

‪‪16.00 M‬‬

Revenue

Net income

Net margin %

Revenue to profit conversion

Revenue

COGS

Gross profit

Op expenses

Op income

Non-Op income/ expenses

Taxes & Other

Net income

‪‪−52.00 M‬‬

‪‪−39.00 M‬‬

‪‪−26.00 M‬‬

‪‪−13.00 M‬‬

‪0.00‬

Revenue

COGS

Gross profit

Expenses & adjustments

Net income

‪‪−48.00 M‬‬

‪‪−36.00 M‬‬

‪‪−24.00 M‬‬

‪‪−12.00 M‬‬

‪0.00‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business

Period: 2024

Gene Therapeutics

By country

Period: 2024

United States

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue

Q2 '24

Q3 '24

Q4 '24

Q1 '25

Q2 '25

‪0.00‬

‪‪250.00 K‬‬

‪‪500.00 K‬‬

‪‪750.00 K‬‬

‪‪1.00 M‬‬

Actual

Estimate

Earnings

Next:Aug 18, 2025

Q2 '24

Q3 '24

Q4 '24

Q1 '25

Q2 '25

‪−2.40‬

‪−1.80‬

‪−1.20‬

‪−0.60‬

‪0.00‬

Actual

Estimate

Dividends

Dividend yield, history and sustainability

No dividends

ADVM has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Q1 '25

‪‪−50.00 M‬‬

‪0.00‬

‪‪50.00 M‬‬

‪‪100.00 M‬‬

‪‪150.00 M‬‬

Debt

Free cash flow

Cash & equivalents

Financial position analysis

Short term

Long term

‪0.00‬

‪‪25.00 M‬‬

‪‪50.00 M‬‬

‪‪75.00 M‬‬

‪‪100.00 M‬‬

Assets

Liabilities